参考文献/References:
[1] VALADE S, MARIOTTE E, AZOULAY E. Coagulation disorders in hemophagocytic lymphohistiocytosis/macrophage activation syndrome[J]. Critical Care Clinics, 2020, 36(2): 415-426.
[2] 王玲, 尹春燕, 肖延风, 等.噬血细胞综合征(HPS)的早期鉴别诊断和实验室结果分析[J]. 现代检验医学杂志, 2016, 31 (4): 107-109. WANG Ling, YIN Chunyan, XIAO Yanfeng, et al. Analysis of the etiology and clinical features of bone marrow in children with hemophagocytic phenomenon[J]. Journal of Modern Laboratory Medicine, 2016, 31(4): 107-109.
[3] HENDERSON L A, CRON R Q. Macrophage activation syndrome and secondary hemophagocytic lymphohistiocytosis in childhood inflammatory disorders: diagnosis and management[J]. Pediatric Drugs, 2020, 22(1): 29-44.
[4] SOY M, ATAG?ND?Z P, ATAG?ND?Z I, et al. Hemophagocytic lymphohistiocytosis: a review inspired by the COVID-19 pandemic[J]. Rheumatology International, 2021, 41(1): 7-18.
[5] 张景荣, 梁筱灵, 靳蓉, 等. HLH-2004 方案诊治儿童噬血细胞综合征临床分析[J]. 中国当代儿科杂志,2013,15(8):686-688. ZHANG Jingrong, LIANG Xiaoling, JIN Rong, et al. HLH-2004 protocol:diagnostic and therapeutic guidelines for childhood hemophagocytic lymphohistiocytosis[J]. Chinese Journal of Contemporary Pediatrics,2013, 15(8): 686-688.
[6] GRIFFIN G, SHENOI S, HUGHES G C. Hemophagocytic lymphohistiocytosis: An update on pathogenesis,diagnosis, and therapy[J]. Best Practice & Research. Clinical Rheumatology, 2020, 34(4): 101515.
[7] YAO Shuyan, WANG Yini, SUN Yuan, et al. Epidemiological investigation of hemophagocytic lymphohistiocytosis in China[J]. Orphanet Journal of Rare Diseases, 2021, 16(1): 342.
[8] 黄文锋, 孔繁聪, 李菲.白细胞介素-6 阻滞治疗在噬血细胞性淋巴组织细胞增生症中的研究新进展[J]. 国际输血及血液学杂志, 2022, 45(2): 106-112. HUANG Wenfeng, KONG Fancong, LI Fei. Research advances on interleukin-6 blocking therapy in treatment of hemophagocytic lymphohistiocytic hyperplasia[J].International Journal of Blood Transfusion and Hematology,2022, 45(2): 106-112.
[9] NAKASHIMA Y, KOGA H. Using a minimal parameter set for early diagnosis of hemophagocytic lymphohistiocytosis in non-european children[J]. Am J Case Rep, 2022, 23:e934037.
[10] CHIN M, MUGISHIMA H, TAKAMURA M, et al. Hemophagocytic syndrome and hepatosplenic gammadelta T-cell lymphoma with isochromosome 7q and 8 trisomy[J]. Journal of Pediatric Hematology Oncology, 2004, 26(6): 375-378.
[11] WANG Siwen, YANG Lichuan, ZHOU Jiaojiao, et al. A prediction model for acute kidney injury in adult patients with hemophagocytic lymphohistiocytosis [J].Front Immunol, 2022, 13: 987916.
[12] B?BOL-POKORA K, WO?OWIEC M, POPKO K, et al. Molecular genetics diversity of primary hemophagocytic lymphohistiocytosis among Polish pediatric patients[J]. Archivum Immunologiae et Therapiae Experimentalis, 2021, 69(1): 31.
[13] LEE D E, MARTINEZ-ESCALA M E, SERRANO L M, et al. Hemophagocytic lymphohistiocytosis in cutaneous T-Cell lymphoma[J]. JAMA Dermatology (Chicago, Ill.), 2018, 154(7): 828-831.
[14] WAKIGUCHI H, HASEGAWA S, HIRANO R, et al. Successful control of juvenile dermatomyositisassociated macrophage activation syndrome and interstitial pneumonia: distinct kinetics of interleukin-6 and -18 levels [J]. Pediatr Rheumatol Online J, 2015,13:49.
[15] NANNO S, KOH H, NAKASHIMA Y, et al. Diagnostic value of serum ferritin and the risk factors and cytokine profiles of hemophagocytic syndrome following allogeneic hematopoietic cell transplantation[J].Leukemia & Lymphoma, 2017, 58(7): 1664-1672.
[16] KARPENKO M N, VASILISHINA A A, GROMOVA E A, et al. Interleukin-1β, interleukin-1 receptor antagonist, interleukin-6, interleukin-10, and tumor necrosis factor-α levels in CSF and serum in relation to the clinical diversity of Parkinson's disease [J]. Cell Immunol, 2018, 327:77-82.
相似文献/References:
[1]张 劲,明 媚.增生性糖尿病视网膜病变患者玻璃体、房水和血浆中VEGF表达与IL-6,IL-8和TNF-α水平的相关性研究[J].现代检验医学杂志,2021,36(04):55.[doi:10.3969/j.issn.1671-7414.2021.04.012]
ZHANG Jin,MING Mei.Correlation of VEGF Expression with IL-6, IL-8 and TNF-α Levels inVitreous Body, Aqueous Humor and Plasma of Patients with ProliferativeDiabetic Retinopathy[J].Journal of Modern Laboratory Medicine,2021,36(06):55.[doi:10.3969/j.issn.1671-7414.2021.04.012]
[2]王 海,肖 华,陈兴壮.血浆miR-223-3p,PCT,IL-6和CRP水平联合检测对脓毒症实验诊断及预后的价值研究[J].现代检验医学杂志,2021,36(05):51.[doi:10.3969/j.issn.1671-7414.2021.05.011]
WANG Hai,XIAO Hua,CHEN Xing-zhuang.Value of Combined Detection of Plasma miR-223-3p, PCT, IL-6 and CRPLevels in Experimental Diagnosis and Prognosis of Sepsis[J].Journal of Modern Laboratory Medicine,2021,36(06):51.[doi:10.3969/j.issn.1671-7414.2021.05.011]
[3]宋婷阁,张鹏举,耿 彪,等.新生儿急性呼吸窘迫综合征患者血清miR-183-5p的表达及与IL-1β,IL-6和TNF-α水平的相关性[J].现代检验医学杂志,2021,36(05):55.[doi:10.3969/j.issn.1671-7414.2021.05.012]
SONG Ting-ge,ZHANG Peng-ju,GENG Biao,et al.Expression of Serum miR-183-5p in Patients with Neonatal Acute RespiratoryDistress Syndrome and Its Correlation with IL-1 β, IL-6 and TNF-α[J].Journal of Modern Laboratory Medicine,2021,36(06):55.[doi:10.3969/j.issn.1671-7414.2021.05.012]
[4]梁 津,刘轾彬,梁成员,等.初诊活动性肺结核患者血浆IL-6,IL-17,IL-37及TIM-3水平表达及其临床意义[J].现代检验医学杂志,2021,36(06):179.[doi:10.3969/j.issn.1671-7414.2021.06.039]
LIANG Jin,LIU Zhi-bin,LIANG Cheng-yuan,et al.Expression and Clinical Significance of Plasma IL-6, IL-17, IL-37 and TIM-3 in Patients with Newly Diagnosed Active Pulmonary Tuberculosis[J].Journal of Modern Laboratory Medicine,2021,36(06):179.[doi:10.3969/j.issn.1671-7414.2021.06.039]
[5]那将超,狄长安.甲状腺乳头状癌患者术后血清MMIF 和IL-6 表达水平与甲状旁腺功能减退持续时间的相关性研究[J].现代检验医学杂志,2023,38(01):191.[doi:10.3969/j.issn.1671-7414.2023.01.036]
NA Jiang-chao,DI Chang-an.Correlation between Postoperative Serum MMIF and IL-6 Expression Levels and Duration of Hypoparathyroidism in Patients with Papillary Thyroid Cancer[J].Journal of Modern Laboratory Medicine,2023,38(06):191.[doi:10.3969/j.issn.1671-7414.2023.01.036]
[6]唐红辉,李洪春.基于吖啶酯化学发光免疫定量分析技术建立血清IL-6 水平检测方法与初步应用评价[J].现代检验医学杂志,2024,39(04):175.[doi:10.3969/j.issn.1671-7414.2024.04.032]
TANG Honghui,LI Hongchun.Establishment of the Detection Method of Serum IL-6 Level and Its Preliminary Application Evaluation based on Acridine Ester Chemiluminescence Immune Quantitative Analysis Technology[J].Journal of Modern Laboratory Medicine,2024,39(06):175.[doi:10.3969/j.issn.1671-7414.2024.04.032]